Vistagen Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended March 31, 2022 (FY2022), with FY2021 comparisons. This is an annual filing, not a report for calendar Q4 2021; the filing separately reports FY2022’s final quarter, ended March 31, 2022.
Business context
Vistagen is a clinical-stage CNS biopharmaceutical company with no approved products or product-sale revenue. Its lead candidate, PH94B, was in two Phase 3 studies and a long-term safety study for acute social anxiety disorder (SAD). PH10 was being prepared for further development in major depressive disorder (MDD), and AV-101 with probenecid was in an exploratory Phase 1B study.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue, all sublicense revenue | $1.109 million | $1.090 million |
| Research and development expense | $35.408 million | $11.926 million |
| General and administrative expense | $13.480 million | $7.098 million |
| Operating loss | $47.779 million | $17.934 million |
| Net loss | $47.762 million | $17.934 million |
| Net loss attributable to common stockholders per share | $0.25 | $0.49 |
| Net cash used in operating activities | $45.257 million | $12.074 million |
| Cash and cash equivalents at year-end | $68.135 million | $103.108 million |
FY2022 revenue came from recognizing part of the $5.0 million AffaMed upfront license payment over the contract service period; it was not product sales. The company reported no meaningful product gross margin. R&D and G&A rose substantially as it advanced PH94B trials, expanded staffing, and incurred pre-commercialization research and analysis costs.
At March 31, 2022, total assets were $74.643 million and total liabilities were $9.928 million. Current assets were $70.998 million versus current liabilities of $5.765 million. The filing reports no material outstanding borrowing at year-end; operating lease liabilities totaled $3.039 million. Cash declined $34.973 million during FY2022; financing activities provided $10.484 million.
Despite year-end cash, management said funding would likely be insufficient for planned operations for the 12 months following issuance of the statements if PH94B development succeeded and commercialization preparations expanded. The auditor highlighted substantial doubt about the company’s ability to continue as a going concern.
Changes, outlook and key risks
- Net loss increased to $47.762 million from $17.934 million, principally as R&D expense rose by about $23.5 million and G&A by about $6.4 million. Operating cash use also increased materially.
- FY2021 common-stockholder loss included a $23.0 million noncash beneficial conversion feature on Series D preferred stock, contributing to the prior-year per-share loss; all preferred shares had been converted by FY2022 year-end.
- FY2022 was funded in part by warrant exercises and ATM sales. The company had a $75 million ATM authorization but reported no ATM sales after October 1, 2021 through the filing date. Further equity financing could dilute shareholders; debt or partnering could impose restrictions or require giving up rights.
- At filing, management anticipated PALISADE-1 topline results in mid-2022 and PALISADE-2 results later in 2022. These were expectations stated at the time, not reported outcomes. Plans also included advancing PH94B, preparing PH10 for Phase 2B, and completing the AV-101/probenecid study.
- Key uncertainties include clinical efficacy and safety, FDA review and additional study requirements, reliance on CROs and contract manufacturers, COVID-related enrollment and supply delays, competition, reimbursement and pricing, and intellectual-property protection. The company also disclosed that previously identified internal-control material weaknesses were remediated by March 31, 2022; the auditor did not audit internal-control effectiveness.
- There were no legal proceedings reported. AffaMed milestone payments of up to $172 million and future royalties were contingent and not assured.
Important facts for investors to verify
- Current cash, quarterly operating cash use, and financing needs against the stated going-concern uncertainty.
- Actual PALISADE-1 and PALISADE-2 results, safety-study progress, and any subsequent FDA feedback or trial requirements.
- Whether PH10 and AV-101 programs advanced as planned, and the funding required to support them.
- Fully diluted share count, outstanding options and warrants, remaining ATM capacity, and potential dilution from future financing.
- AffaMed’s development progress and whether any contractual milestone or royalty conditions have been met.